

Corporate Sponsored Presentations

Session Time (ET)	Abstract #/Title/Lead Author	Type/Session
Saturday, March 16, 2024		
Saturday, March 16, 2024 6:45AM-7:45AM Ballroom 20AB	428204 / Tisotumab Vedotin HEOR Seeing Health Disparities in Cervical Cancer: Mapping Behavioral and Socioeconomic Drivers of Geographic Dispersion of Disease Burden with the Geo-Analyzer Tool Lead Author: Castellano	Special Interest Oral Session
Saturday, March 16, 2024 8:30AM-9:45AM Hall F	568638 / Tisotumab Vedotin innovaTV 301 Efficacy and Safety of Tisotumab Vedotin Versus Investigator's Choice of Chemotherapy in 2L or 3L Recurrent or Metastatic Cervical Cancer (innovaTV 301/ENGOT-cx12/GOG-3057): A Global, Randomized, Open-Label, Phase 3 Study Lead Author: Slomovitz	Oral Presentation
Monday, March 18, 2024		
Monday, March 18, 2024 11:45AM-12:45PM Hall GH	448275 / Tisotumab Vedotin HEOR Patients with advanced cervical cancer value disease control and overall survival in treatment decision-making: a US patient preference study Lead Author: Thaker	Poster Session
Monday, March 18, 2024 11:45AM-12:45PM Hall GH	481945 / Disitamab Vedotin DV-005 Phase 2 Basket Study of Disitamab Vedotin in Patients With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors That Express HER2: Ovarian and Endometrial Cancer Cohorts (DV-005; Trial in Progress) Lead Author: Liu	Poster Session

Seagen is now part of Pfizer! Please visit [Pfizer.com](https://www.pfizer.com) for more information.

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

